Navigation Links
PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
Date:9/8/2009

statements, including regarding PDL's expectations with respect to its 2009 royalty revenues.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
  • The ability to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • Changes in any of the other assumptions including foreign currency exchange rates on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as re
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix BioPharma Announces $13.5 Million Private Placement
2. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
3. DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
4. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
5. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
6. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
9. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
10. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
11. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... November 20, 2014 BlueInGreen, LLC ... Solutions, LLC (Pinnacle), and PCI, Inc., leading suppliers ... they have been selected to provide a new ... Arkansas Paul R. Noland Wastewater Treatment. The ... HyDOZ® gas dissolution technology, Pinnacle Ozone’s ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/18/2014)... BRUNO, Calif. , Nov. 18, 2014 ... a platinum sponsor of the 10th Annual World Stem Cell ... regenerative medicine stakeholders. The 2014 World Stem Cell Summit will ... San Antonio, Texas . The ... discovery and development of lifesaving cures and therapies, convening the ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
Breaking Biology Technology:City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
... (Nasdaq: GENR ) today announced that Jack Armstrong, President,and ... the BIO,Business Forum. The presentation will provide an update on ... Convention Center in San,Diego on Tuesday, June 17, 2008 at ... join a panel of experts to discuss new advancements,in the ...
... Program Supports Development of Strong Scientific Capacity in ... Charitable,Trusts and the University of California at San ... have been named 2008 Pew,Latin American Fellows in ... to UCSF, the highly competitive fellowship program offers ...
... community, LISLE, Ill., June 12 ... retirement community located in Chicago,s,western suburbs, announces ... site,( http://www.VillaStBen.org ). The new site depicts ... in-depth information and support for,residents, prospective seniors, ...
Cached Biology Technology:Genaera Corporation to Present at BIO Business Forum 2Genaera Corporation to Present at BIO Business Forum 3Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences 2Villa St. Benedict Announces New Web Site 2
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... researchers think their discovery of the enzyme involved in ... lead not only to better pest control, but also ... aircraft and armor. , After a beetle first molts, ... out and forms a hard, stiff exoskeleton. Since the ...
... antibody engineered by scientists at The University of Texas ... the use of antibiotics and other more expensive antibodies. ... both anthrax bacteria and its deadly toxins in animal ... first successful treatment for late-stage anthrax infection, even for ...
... at Stanford University have created a larger-than-normal DNA molecule ... The findings, reported in the Oct. 25 online edition ... (PNAS), may reveal new insights into how genetic mutations-tiny ... made in the laboratory of Eric Kool, a professor ...
Cached Biology News:K-State professors discover enzyme responsible for creation of a beetle's hard shell 2New antibody shows promise as cure for anthrax 2New antibody shows promise as cure for anthrax 3DNA size a crucial factor in genetic mutations, study finds 2DNA size a crucial factor in genetic mutations, study finds 3
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
... The Experion HighSens analysis kit for 25 ... to perform high-sensitivity RNA analysis (at picogram ... This kit includes 25 RNA HighSens microfluidic ... 2 x 20 microliters RNA HighSens stain, ...
Biology Products: